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Voriconazole concentrations display a large variability, which cannot completely be explained by known factors. Inflammation
may be a contributing factor, as inflammatory stimuli can change the activities and expression levels of cytochrome P450 isoen-
zymes. We explored the correlation between inflammation, reflected by C-reactive protein (CRP) concentrations, and voricona-
zole trough concentrations. A retrospective chart review of patients with at least one steady-state voriconazole trough concentra-
tion and a CRP concentrationmeasured on the same day was performed. A total of 128 patients were included. A significantly
(P< 0.001) higher voriconazole trough concentration was observed in patients with severe inflammation (6.2 mg/liter; inter-
quartile range [IQR], 3.4 to 8.7 mg/liter; n 20) than in patients with moderate inflammation (3.4 mg/liter; IQR, 1.6 to 5.4 mg/
liter; n 60) and in patients with no to mild inflammation (1.6 mg/liter; IQR, 0.8 to 3.0 mg/liter; n 48). The patients in all
three groups received similar voriconazole doses based onmg/kg body weight (P 0.368). Linear regression analyses, both un-
adjusted and adjusted for covariates of gender, age, dose, route of administration, liver enzymes, and interacting coadministered
medications, showed a significant association between voriconazole and CRP concentration (P< 0.001). For every 1-mg/liter
increase in the CRP concentration, the voriconazole trough concentration increased by 0.015 mg/liter (unadjusted 95% confi-
dence interval [CI], 0.011 to 0.020 mg/liter; adjusted 95% CI, 0.011 to 0.019 mg/liter). Inflammation, reflected by the C-reactive
protein concentration, is associated with voriconazole trough concentrations. Further research is necessary to assess if taking the
inflammatory status of a patient into account is helpful in therapeutic drug monitoring of voriconazole to maintain concentra-
tions in the therapeutic window, thereby possibly preventing suboptimal treatment or adverse events.
Voriconazole, a broad-spectrumantifungal agent, is considereda first-line agent for the treatment of invasive aspergillosis (1).
Several studies showed a relation between the efficacy and safety of
voriconazole and voriconazole trough concentrations (2–7).
Voriconazole trough concentrations of 1.5 mg/liter are associ-
ated with a favorable response to treatment. High voriconazole
trough concentrations are associated with an increased incidence
of adverse events, such as visual disturbances, hallucinations, and
abnormalities in liver enzyme levels. The Infectious Diseases So-
ciety of America guidelines recommend determination of vori-
conazole concentrations in conjunction with other measures of
clinical assessment to evaluate potential toxicity or to document
adequate voriconazole exposure (1).
In daily practice, a large variability in voriconazole concentrations
is observed, not only between patients (8) but also within individual
patients over time (9). Polymorphisms of cytochrome P450 isoen-
zymes (10), impaired liver function (11), and drug-drug interactions
(12) influence voriconazole pharmacokinetics but donot completely
explain the observed variability. Therefore, other factors may con-
tribute to the variability of voriconazole pharmacokinetics.
We expect that inflammation may be one of these factors. In-
fections or inflammatory stimuli can change the activities and
expression levels of various forms of cytochromeP450 isoenzymes
(13). The downregulation of cytochrome P450 isoenzymes during
inflammation decreases the hepatic clearance of drugs that are
metabolized by these enzymes. As voriconazole is extensively me-
tabolized by cytochrome P450 isoenzymes 2C19, 3A4, and 2C9
(14), inflammation may contribute to the variability of the phar-
macokinetics of voriconazole.
The aim of this retrospective study was to investigate whether
inflammation, reflected by C-reactive protein (CRP) concentra-
tions, is associated with voriconazole trough concentrations.
MATERIALS AND METHODS
A retrospective chart reviewwas performed for all patients aged18 years
who had at least one steady-state voriconazole trough concentration and
aCRP concentrationmeasured on the same day. The patients were treated
at the University Medical Center Groningen, The Netherlands, between
January 2006 andDecember 2010. Patientswhowere concomitantly using
a strong inhibitor or inducer of cytochrome P450 isoenzymes were ex-
cluded. Steady state was considered to be achieved after 6 doses when 2
loading doses were administered (15), after 10 doses when 2 loading
doses were administered (16), and at 6 doses after a dosage adjustment
(17). We measured voriconazole serum concentrations using a validated
method that involved liquid chromatography coupled with tandem-mass
spectrometry (18). This study was evaluated by the local ethics committee
(IRB 2013-491) and was in accordance with Dutch law because of its
retrospective nature.
For each eligible patient, data that included demographic details,med-
ical history, and laboratory parameters were collected from the medical
chart. In addition to the voriconazole trough and CRP concentrations,
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alkaline phosphatase, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), -glutamyl transferase (GT), and total bilirubin con-
centrations were collected. Information on voriconazole treatment was
also gathered. In addition, we evaluated medication used concomitantly
that may have influenced the voriconazole concentrations by means of
interactions with cytochrome P450 isoenzymes 2C19 and 3A4.
Numerical variables are summarized as medians and interquartile
ranges (IQRs), and categorical variables are summarized as frequencies
and percentages.
To explore the possible association of inflammationwith voriconazole
trough concentrations, voriconazole trough concentrations of patients
with no to mild inflammation (CRP,40 mg/liter), those with moderate
inflammation (CRP, 41 to 200mg/liter), and those with severe inflamma-
tion (CRP,200mg/liter) (19, 20)were compared using aKruskal-Wallis
test. A linear regression analysis was performed to assess the contribution
of inflammation, reflected by CRP concentrations, to the variability in
voriconazole trough concentrations, both unadjusted and adjusted for the
gender, age, dose, route of administration, alkaline phosphatase, ALT,
AST, GT, total bilirubin, and interacting comedication covariates. We
corrected for these variables as much as possible to determine the direct
association of inflammation (reflected by CRP concentrations) with vori-
conazole trough concentrations. For each patient, only the first steady-
state voriconazole trough concentration with a CRP concentration mea-
sured on the same day was used for analysis. These analyses were
performed with IBM SPSS 22.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Based on data from the hospital information system, we selected
patients who had a steady-state voriconazole trough concentra-
tion and a CRP concentrationmeasured on the same day. Of these
133 patients, 128 patients were included in our analysis. Five pa-
tients were excluded because they concomitantly used phenytoin
(n 2), rifampin (n 2), or HIV medication (n 1).
The patient characteristics are shown in Table 1. The median
values of most laboratory parameters were inside their respective
normal ranges. CRP andGTconcentrationswere higher than the
upper limit of normal. Regardingmedication used concomitantly,
which potentially influenced voriconazole concentrations, only
omeprazole and esomeprazole were used simultaneously with
voriconazole.
A significantly (P 0.001) higher voriconazole trough concen-
tration was observed in patients with severe inflammation (6.2
[IQR, 3.4 to 8.7] mg/liter; n 20) than in patients with moderate
inflammation (3.4 [1.6 to 5.4] mg/liter; n  60) and no to mild
inflammation (1.6 [0.8 to 3.0]mg/liter; n 48). These differences
are shown in Fig. 1. The patients in all three groups received sim-
ilar doses of voriconazole (P  0.368) twice daily. The median
(IQR) voriconazole doseswere 3.0 (2.5 to 3.8)mg/liter for patients
with no tomild inflammation, 3.6 (2.7 to 3.9)mg/liter for patients
with moderate inflammation, and 3.5 (2.9 to 4.0) mg/liter for
patients with severe inflammation. Of the 48 patients with a CRP
concentration of 40 mg/liter, only one patient (2.1%) had a
voriconazole trough concentration of5 mg/liter (5.8 mg/liter).
Of the 20 patients with a CRP concentration of 200 mg/liter,
none had a voriconazole trough concentration of1.5 mg/liter.
The association betweenCRP concentrations and voriconazole
trough concentrationswas significant in both the unadjusted (P
0.001) and adjusted (P  0.001) linear regression analyses. For
every 1-mg/liter increase in the CRP concentration, the voricona-
zole trough concentration increased by 0.015 mg/liter in each of
the two analyses (unadjusted 95% confidence interval [CI], 0.011
to 0.020 mg/liter; adjusted 95% CI, 0.011 to 0.019 mg/liter). The
adjusted linear regression analysis explained 46% of the variance
in the voriconazole trough concentrations. Figure 2 shows the
voriconazole and CRP concentrations of a patient during treat-
ment with voriconazole.
TABLE 1 Patient characteristicsa
Characteristic
No. (%) of patients or
median (IQR)
Demographic
Gender (female) 59 (46)
Age (yr) 55 (42–62)
Weight (kg) 75 (61–85)
Height (m) 1.75 (1.67–1.81)
BMIb (kg/m2) 24.2 (21.6–26.6)
Underlying disease
Hematologic malignancy 67 (52)
Solid organ transplant 34 (27)
Otherc 27 (21)
Voriconazole treatment
Twice-daily dose (mg/kg) 3.3 (2.6–3.9)
Intravenous administration 64 (50)
Laboratory parameter
Voriconazole (mg/liter) 2.7 (1.3–4.8)
CRP (mg/liter) 71 (15–152)
Alkaline phosphatase (U/liter) 114 (71–192)
ALT (U/liter) 36 (17–69)
AST (U/liter) 31 (19–61)
-Glutamyl transferase (U/liter) 105 (55–232)




b BMI, body mass index.
c Other diagnosed diseases included chronic pulmonary obstructive disease, cystic
fibrosis, and granulomatosis with polyangiitis.
FIG 1 Box (median and 25th to 75th percentiles) and whisker (5th and 95th
percentiles) plots of voriconazole trough concentrations for patients with no
to mild inflammation (n 48), moderate inflammation (n 60), and severe
inflammation (n  20). The filled circles represent outliers. The median (in-
terquartile range [IQR]) voriconazole dose (inmg/kg of body weight) for each
group is displayed above each box-and-whisker plot. The dotted lines repre-
sent the therapeutic window of voriconazole trough concentrations.
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This is the first study to show that inflammation, reflected by
C-reactive protein concentrations, is associated with voriconazole
trough concentrations. The multiple linear regression analysis
showed that, for every 1-mg/liter increase in the CRP concentra-
tion, the voriconazole trough concentration was 0.015 mg/liter
higher. These results provide a possible explanation for some of
the variability in voriconazole concentrations.
Inflammation is associated with the variability observed be-
tween and within patients at different time points, regardless of
polymorphisms of cytochrome P450 isoenzymes (10), impaired
liver function (11), and drug-drug interactions (12), which are
already known to influence voriconazole pharmacokinetics. The
inflammatory status of patients is different and can change over
time during voriconazole treatment, which alters inflammatory
cytokine concentrations. The inflammatory cytokines cause a
downregulation of cytochrome P450 isoenzymes at the level of
gene transcription, which results in a decrease in the correspond-
ing mRNA, protein, and enzyme activities (13, 21–23). These de-
creases change the rate of the metabolism of voriconazole,
resulting in variable voriconazole concentrations. Trifilio et al.
hypothesized that the observed variability is caused by multiple
factors, including changes in absorption, patient protein status,
liver function, and disease-modifying effects, such as graft-versus-
host disease (9). Long-term exposure to voriconazole has been
suggested to cause autoinduction of cytochrome P450 isoen-
zymes, resulting in decreasing voriconazole concentrations (24).
However, autoinduction has not been seen in healthy human vol-
unteers (25).
A limitation of this study is its retrospective nature, which pos-
sibly introduced selection bias and limited the availability of de-
sired data. The impact of selection bias on the results was expected
to be limited, given that voriconazole concentrations were mea-
sured in most patients in our hospital, not only when efficacy or
safetywas in question. Information on the genetic polymorphisms
of the cytochrome P450 isoenzymes in individual patients was not
available, because these data were not determined in routine pa-
tient care. Therefore, we could explain only a part of the variability
of voriconazole pharmacokinetics. Cytochrome P450 polymor-
phisms contribute to the variability of voriconazole pharmacoki-
netics between patients (10). Polymorphisms might explain some
of the pharmacokinetic variability of voriconazole, in particular
the unexplained variability in our model. It is unlikely that poly-
morphisms completely explain the observed variability, because
the prevalence of poor metabolizers of CYP2C19, who likely con-
tribute most to the variability in voriconazole trough concentra-
tions between patients, is only 3% to 5% in the Caucasian popu-
lation (26).
CRP concentrations were used as markers for inflammatory
status because the concentrations of inflammatory cytokines were
not available in this retrospective study. Cytokines stimulate the
production of acute-phase proteins; CRP concentrations in par-
ticular change rapidly when the inflammatory status of a patient
changes (27). As a result, CRP concentrations are used extensively
in daily practice as markers for inflammation.
Further research that includes information about cytochrome
P450 isoenzyme polymorphisms is necessary. We suggest a pro-
spective study to investigate if a dosing algorithm can be devel-
FIG 2 Voriconazole trough concentrations (solid curve) and CRP concentrations (dashed curve) of a 46-year-old male patient with cystic fibrosis who was
admitted to the intensive care unit with respiratory insufficiency and was treated with voriconazole after Aspergillus fumigatus was isolated from his respiratory
secretions. On day 24, the patient received a bilateral lung transplant. The dotted lines represent the therapeutic window of voriconazole.
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oped to predict the voriconazole concentration on the basis of
patient characteristics and voriconazole dose and route of admin-
istration.
In conclusion, we have shown that inflammation, reflected by
the CRP concentration, is associated with voriconazole trough
concentrations. Further research is necessary to assess if account-
ing for the inflammatory status of a patient is helpful in therapeu-
tic drugmonitoring of voriconazole tomaintain concentrations in
the therapeutic window, thereby possibly preventing suboptimal
treatment or adverse events.
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